Illumina Inc. introduced a new line of gene-sequencing machines that the company says can more than double capacity versus prior sequencers, while reducing the cost per genome. The rollout, which ...

Bangalore (Reuters) - Companies that make the gene-sequencing devices used in scientific research face a tough few years as potential cuts to the U.S. federal budget squeeze funding to its main ...

llumina on Thursday forecast core business revenue to be nearly flat in the coming year compared to 2023 amid subdued demand for its genetic testing tools and diagnostics products. The San Diego-based ...

Most biopharma players need access to gene sequencing services. Illumina is facing a handful of headwinds, but it's still the market leader. Bionano Genomics is unproven but expanding quickly. So ...

SANTA CLARA, CA--(Marketwire - Oct 31, 2012) - NVIDIA® Tesla® GPU accelerators are enabling Life Technologies Corporation's new Ion Proton™ System to accelerate primary genome-sequence analysis-- the ...

Elucidating the relationship between the sequences of non-coding regulatory elements and their target genes is key to understanding gene regulation and its variation between plant species and ecotypes ...

Companies like Ultima Genomics say they have the technology, which could lead to medical breakthroughs. But similar promises in the past have fizzled and barriers remain. By Roy Furchgott This article ...

With shares of the gene sequencing giant Illumina (NASDAQ: ILMN) collapsing by 53% over the last three years due to a combination of a botched acquisition attempt and weakness in its core business, ...